Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Merkel cell carcinoma.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Science: general issues --- Medical microbiology & virology --- Microbiology (non-medical) --- papillomaviruses human --- polyomaviruses human --- viral oncogenesis --- Hit-and-Run carcinogenesis --- Field cancerization --- Skin Cancer --- merkel cell carcinoma --- Cutaneous squamous cell carcinoma --- BRAF inhibitors --- papillomaviruses human --- polyomaviruses human --- viral oncogenesis --- Hit-and-Run carcinogenesis --- Field cancerization --- Skin Cancer --- merkel cell carcinoma --- Cutaneous squamous cell carcinoma --- BRAF inhibitors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Merkel Cell Carcinoma is one of the first comprehensive, single-source clinical texts on the subject. Although not as common as melanoma, Merkel cell carcinoma is not rare – and it is both more deadly than melanoma and increasing at an epidemic rate. The book is clinical in focus and emphasizes treatment of this poorly understood cancer. Contributing authors include dermatologists, surgical oncologists, radiation oncologists, and medical oncologists from the US and around the world. Features: Comprehensive single-source clinical reference Treatment focus Written for practitioners, with emphasis on clinical relevance and quick retrieval of information Contributing authors represent all disciplines involved in treatment of Merkel cell carcinoma: dermatology, surgical oncology, radiation oncology, and medical oncology International in perspective, with contributors from US and abroad Members of active Merkel Cell Carcinoma Multicenter Interest Group have authored some of the chapters.

Carcinoma, Merkel cell. --- Medicine. --- Merkel cell carcinoma. --- Merkel cell carcinoma --- Medicine --- Neoplasms by Site --- Carcinoma, Neuroendocrine --- Mechanoreceptors --- Neoplasms --- Health Occupations --- Sensory Receptor Cells --- Neuroendocrine Tumors --- Neuroectodermal Tumors --- Neurons, Afferent --- Disciplines and Occupations --- Diseases --- Neurons --- Neoplasms, Germ Cell and Embryonal --- Neoplasms by Histologic Type --- Nervous System --- Anatomy --- Carcinoma, Merkel Cell --- Merkel Cells --- Pathology --- Skin Neoplasms --- Health & Biological Sciences --- Dermatology --- Merkel cells. --- Cancer. --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Dermatology. --- Oncology. --- Surgical oncology. --- Medicine & Public Health. --- Surgical Oncology. --- Tumors --- Epithelial cells --- Oncology  . --- Cancer --- Oncologic surgery --- Oncological surgery --- Surgical oncology --- Skin --- Excision --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.

Medicine --- mTOR --- histone deacetylase --- prostate cancer --- integrins --- adhesion --- invasion --- cell metabolism --- T cells --- Foxp3 --- Acute Lymphoblastic leukemia --- targeted therapy --- metabolism --- cell signalling --- mTOR signalling --- head and neck cancer --- mutant genes --- biomarkers --- targeted therapies --- clinical trials --- cancers --- inhibitors --- photodynamic therapy --- PI3K --- Akt --- skin cancers --- phytochemicals --- melanoma --- basal cell carcinoma --- squamous cell carcinoma --- Merkel cell carcinoma --- TNBC --- eribulin --- PI3K/AKT/mTOR --- everolimus --- combination --- synergy --- mTOR signaling --- tissue regeneration --- neuron --- muscle --- liver --- intestine --- hematologic malignancies --- regulatory T cells --- tumor --- mTOR --- histone deacetylase --- prostate cancer --- integrins --- adhesion --- invasion --- cell metabolism --- T cells --- Foxp3 --- Acute Lymphoblastic leukemia --- targeted therapy --- metabolism --- cell signalling --- mTOR signalling --- head and neck cancer --- mutant genes --- biomarkers --- targeted therapies --- clinical trials --- cancers --- inhibitors --- photodynamic therapy --- PI3K --- Akt --- skin cancers --- phytochemicals --- melanoma --- basal cell carcinoma --- squamous cell carcinoma --- Merkel cell carcinoma --- TNBC --- eribulin --- PI3K/AKT/mTOR --- everolimus --- combination --- synergy --- mTOR signaling --- tissue regeneration --- neuron --- muscle --- liver --- intestine --- hematologic malignancies --- regulatory T cells --- tumor

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.

mTOR --- histone deacetylase --- prostate cancer --- integrins --- adhesion --- invasion --- cell metabolism --- T cells --- Foxp3 --- Acute Lymphoblastic leukemia --- targeted therapy --- metabolism --- cell signalling --- mTOR signalling --- head and neck cancer --- mutant genes --- biomarkers --- targeted therapies --- clinical trials --- cancers --- inhibitors --- photodynamic therapy --- PI3K --- Akt --- skin cancers --- phytochemicals --- melanoma --- basal cell carcinoma --- squamous cell carcinoma --- Merkel cell carcinoma --- TNBC --- eribulin --- PI3K/AKT/mTOR --- everolimus --- combination --- synergy --- mTOR signaling --- tissue regeneration --- neuron --- muscle --- liver --- intestine --- hematologic malignancies --- regulatory T cells --- tumor